Antiphospholipid autoantibodies as blood biomarkers for detection of early stage Alzheimer's disease. (August 2015)

• Record Type: Journal Article
• Authors: McIntyre, John A.; Ramsey, Curtis J.; Gitter, Bruce D.; Saykin, Andrew J.; Wagenknecht, Dawn R.; Hyslop, Paul A.; for the Alzheimer's Disease Neuroimaging Initiative
• Is Part Of: Autoimmunity. Volume 48:Number 5(2015)
• Page Start: 344
• Page End: 351
• Publication Date: 2015-08
• Subjects: Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; 571.973
• DOI: 10.3109/08916934.2015.1008464
• Languages: English
• ISSNs: 0891-6934

Abstract

<abstract> <title>Abstract</title> <p>A robust blood biomarker is urgently needed to facilitate early prognosis for those at risk for Alzheimer's disease (AD). Redox reactive autoantibodies (R-RAAs) represent a novel family of antibodies detectable only after exposure of cerebrospinal fluid (CSF), serum, plasma or immunoglobulin fractions to oxidizing agents. We have previously reported that R-RAA antiphospholipid antibodies (aPLs) are significantly decreased in the CSF and serum of AD patients compared to healthy controls (HCs). These studies were extended to measure R-RAA aPL in serum samples obtained from Alzheimer's Disease Neuroimaging Initiative (ADNI). Serum samples from the ADNI-1 diagnostic groups from participants with mild cognitive impairment (MCI), AD and HCs were blinded for diagnosis and analyzed for R-RAA aPL by ELISA. Demographics, cognitive data at baseline and yearly follow-up were subsequently provided by ADNI after posting assay data. As observed in CSF, R-RAA aPL in sera from the AD diagnostic group were significantly reduced compared to HC. However, the sera from the MCI population contained significantly elevated R-RAA aPL activity relative to AD patient and/or HC sera. The data presented in this study indicate that R-RAA aPL show promise as a blood biomarker for detection of early AD, and warrant replication in a larger sample. Longitudinal testing of an individual for increases in R-RAA aPL over a previously established baseline may serve as a useful early sero-epidemiologic blood biomarker for individuals at risk for developing dementia of the Alzheimer's type.</p> </abstract>